Compound: Leuprorelin
SMILES: O=C1N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2[C@H](C(=O)NCC)CCC2)CCCNC(=N)N)CC(C)C)CC(C)C)Cc3ccc(O)cc3)CO)Cc4c5c(cccc5)[nH]c4)Cc6nc[nH]c6)CC1
InChIKey: GFIJNRVAKGFPGQ-LIJARHBVSA-N
Synonyms: Leuprorelin, leuprolide, 53714-56-0, Leuproreline, Leuprorelinum, Leuporelin, Leuprorelina, (-)-leuprolide, Leuprorelin slow release, EFY6W0M8TG, TAP-144 FREE BASE, CKD-841, ABBOTT-43818 FREE BASE, NSC-377526, CHEBI:6427, DTXSID50872411, pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5, RefChem:55465, DTXCID00820063, L02AE02, 6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig), 6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig), (2S)-1-((2S)-5-carbamimidamido-2-(((2S)-2-(((2R)-2-(((2S)-2-(((2S)-1,3-dihydroxy-2-(((2S)-1-hydroxy-2-(((2S)-1-hydroxy-2-((hydroxy((2S)-5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl)methylidene)amino)-3-(1H-imidazol-5-yl)propylidene)amino)-3-(1H-indol-3-yl)propylidene)amino)propylidene)amino)-1-hydroxy-3-(4-hydroxyphenyl)propylidene)amino)-1-hydroxy-4-methylpentylidene)amino)-1-hydroxy-4-methylpentylidene)amino)pentanoyl)-N-ethylpyrrolidine-2-carboximidic acid, MFCD00167544, C59H84N16O12, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide, Leuprorelin acetate (JAN), Leuprolide acetate (USAN), Leuprolide TFA, LEUPROLIDE [USAN], LEUPRORELIN [INN], Leuprolide acetate salt, Leuprorelin [INN:BAN], UNII-EFY6W0M8TG, Leuproreline [INN-French], Leuprorelinum [INN-Latin], Leuprorelina [INN-Spanish], Leuprorelin?, CCRIS 8462, Leuprorelin CRS, HSDB 6518, NSC 377526, LEUPROLIDE [MI], LEUPROLIDE [HSDB], LEUPROLIDE [VANDF], SCHEMBL4585, LEUPRORELIN [MART.], LEUPRORELIN [WHO-DD], SCHEMBL172917, GTPL1175, CHEMBL1201199, SCHEMBL30983092, GFIJNRVAKGFPGQ-LIJARHBVSA-N, LEUPRORELIN [EP MONOGRAPH], MSK10725, (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-GNRH, (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-LHRH, BDBM50247891, BDBM50369395, EBC-27540, EX-A14831, FP-001, AKOS015892744, AKOS030213246, AKOS037515838, CCG-270656, CS-4947, DB00007, HS-2016, NCGC00485984-01, (2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2R)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-4-methylpentanamido]pentanoyl]-N-ethylpyrrolidine-2-carboxamide, AC-38352, DA-64932, HY-12553, Leuprolide acetate salt, >=98% (HPLC), C75519, pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt, EN300-7481165, Fensolvi (leuprolide acetate injectable suspension), Q907160, BRD-K26323068-001-01-8, Leuprolide acetate, United States Pharmacopeia (USP) Reference Standard, 1-9-Luteinizing hormone-releasing factor (swine), 6-D-leucine-9-(N-ethyl-L-prolinamide)-, 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-Lprolinamide, L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
Theoretical properties:
molecular_formula: C59H84N16O12
molecular_weight: 1209.4 g/mol
exact_mass: 1208.64546218 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 15
hydrogen_bond_acceptor_count: 14
rotatable_bond_count: 32
heavy_atom_count: 87
topological_polar_surface_area: 432 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Fluffy solid
color: Fluffy solid
melting_point: 150-155
Descriptions:
{"pubchem": "Leuprolide is an oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. It has a role as an antineoplastic agent, an anti-estrogen and a gonadotropin releasing hormone agonist.", "chebi": "An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, <small>D</small>-leucyl, leucyl, arginyl, and <em>N</em>-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.", "chembl": "LEUPROLIDE is a protein listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, as part of transgender hormone therapy, or to perform chemical castration of violent sex offenders. It is given by injection into a muscle or under the skin.\nLeuprorelin is in the gonadotropin-releasing hormone (GnRH) analogue family of medications. It works by decreasing gonadotropins, thereby decreasing testosterone and estradiol. Common side effects include hot flashes, unstable mood, trouble sleeping, headaches, and pain at the site of injection. Other side effects may include high blood sugar, allergic reactions, and problems with the pituitary gland. Use during pregnancy may harm foetal development.\nLeuprorelin was patented in 1973 and approved for medical use in the United States in 1985. It is on the World Health Organization's List of Essential Medicines. It is sold under the brand name Lupron, among others."}